Released Presentations

  • IP19 : STRUCTURAL IMPLEMENTATION OF PATIENT PREFERENCES IN HEALTH TECHNOLOGY ASSESSMENT: WILL WE EVER GET THERE? A QUESTION RAISED BY IMI PREFER

    Presentation

    David Mott
    Economist, Office of Health Economics, London, UK
    Dr. Marco Petschulies
    Scientific Advisor, Federal Joint Committee (G-BA), Berlin, Germany
    Eline van Overbeeke
    PhD researcher, University of Leuven, Leuven, Belgium
  • IP25 : Should Nutritional Products Be Evaluated and Reimbursed The Same Way Pharmaceuticals Are?

    Presentation

    Karen Feijer
  • P1 : Aligning Evidence Requirements for Drug Authorization and Coverage –Central and Eastern European (CEE) Countries Insights
  • P2 : Health Data, Health Data, and More Health Data: From Quantity to Quality Through Cooperation
  • P3 : Medical Device Assessment and Procurement - Fair and Efficient Access in Countries with Limited Health Budgets
  • P4 : How Far Can We Go? Finding a Common Way in Clinical Evaluation, Data Generation, and Joint Procurement and Pricing Negotiations
  • PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States

    Presentation

    Finn Børlum Kristensen, MD, PhD
  • PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States

    Presentation

    Roman Topór-Mądry
  • PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States

    Presentation

    Ansgar Hebborn, PhD
  • PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States

    Presentation

    Luciana Ballini
  • PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States

    Presentation

    Menno Aarnout
  • PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States

    Presentation

    Flora Giorgio
  • PL1 : Joint Assessment of Relative Effectiveness: “Trick or Treat” for Decision Makers in EU Member States
  • PL3 : Budget Impact and Expenditure Caps: Potential or Pitfall?

    Presentation

    Félix Lobo, PhD
  • PL3 : Budget Impact and Expenditure Caps: Potential or Pitfall?

    Presentation

    Peter C. Smith, MSc
  • PL3 : Budget Impact and Expenditure Caps: Potential or Pitfall?

    Presentation

    Adrian Towse, MA, MPhil
  • PL3 : Budget Impact and Expenditure Caps: Potential or Pitfall?
  • S1 : Improving Patient Access to Innovative Cancer Therapies: The Role of Managed Entry Agreements
  • S2 : The Implementation of Sustainable Biosimilar Policies to Increase Access to Biological Medicines in CEE Countries
  • W7 : Preference Research in HTA Agencies Europe